&lt;p&gt;Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy&lt;/p&gt;

Bassetti, Matteo; Castaldo, Nadia; Carnelutti, Alessia; Peghin, Maddalena; Giacobbe, Daniele Roberto

doi:10.2147/ce.s187499

Cited by 17 publications

(8 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results on S. aureus biofilm, together with previously available data ( Bassetti et al, 2019 ; Carvalhaes et al, 2019 ), suggest a complementary activity of this combination. Indeed, rifampicin is known to be able to disaggregate S. aureus biofilm, while tedizolid has a good antimicrobial activity against planktonic bacteria and it has been demonstrated that inhibits S. aureus biofilm formation ( Delpech et al, 2018 ; Abad et al, 2019 ).…”

Section: Discussionsupporting

confidence: 85%

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

et al. 2020

View full text Add to dashboard Cite

Staphylococcus aureus infections associated with implanted medical devices are difficult to treat and require long-lasting antibiotic therapies, especially when device removal is not possible or easy such as in the case of joint prostheses. Biofilm formation is a major cause of treatment failure and infection recurrence. This study aimed to test, for the first time, the in vitro combination of tedizolid plus rifampicin on methicillin-sensitive (MSSA ATCC 6538) and methicillin-resistant (MRSA ATCC 43300) S. aureus mature biofilm. Here, we demonstrated that the combination of tedizolid with rifampicin significantly disaggregated pre-formed biofilm of both strains, reduced their metabolic activity and exerted bactericidal activity at clinically meaningful concentrations. Notably, tedizolid was able to completely prevent the emergence of resistance to rifampicin. Moreover these effects were similar to those obtained with daptomycin plus rifampicin, a well-known and widely used combination. Preliminary results on some MRSA clinical isolates confirmed the efficacy of this combination in reducing biofilm biomass and preventing rifampicin resistance onset. Further in vivo studies are needed to confirm the validity of this promising therapeutic option that can be useful against biofilm-associated S. aureus infections.

show abstract

Section: Discussionsupporting

confidence: 85%

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is possible that there was a cumulative effect of oxazolidinone therapy, combining the 8-month tedizolid course with 3-weeks prior exposure to linezolid. Tedizolid has compared favourably to linezolid in studies of ABSSIs [11] . It had non-inferior efficacy and reduced risk of some side effects, including thrombocytopenia, though it is important to note these studies tested short-term therapy (less than 14 days).…”

Section: Discussionmentioning

confidence: 99%

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection

Shaw

Smyth

Turner

et al. 2021

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Cutaneous non-tuberculous mycobacterial (NTM) infections are an emerging infectious disease and require a protracted course of combination antibiotics. Antimicrobial choice is limited by resistance and toxicity. Tedizolid is a new oxazolidinone antibiotic with in vitro activity against some NTM, but its use in the management of extrapulmonary NTM has not been described. We report on the utility of prolonged tedizolid use (8 months), after linezolid intolerance, in combination therapy in a case of difficult Mycobacterium chelonae cutaneous infection. Although tedizolid contributed to clinical remission, it may have also contributed to a multifocal peripheral neuropathy. Its efficacy may also have been limited by continued immunosuppression, with evidence to suggest disease relapse or treatment failure after completion of combination therapy. Tedizolid can be considered, with caution, in combination therapy for difficult cases of cutaneous NTM infection.

show abstract

“…The most common side effects were headache, nausea and QT prolongation [62,63]. It has not been FDA approved for ABSSSI yet for safety concerns [64][65][66][67][68] (Table 1).…”

Section: Iclaprimmentioning

confidence: 99%

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Hindy

Haddad

Kanj

2021

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewStaphylococcus aureus is a pathogen incriminated in skin and soft tissue infections (SSTIs), with methicillinresistant S. aureus (MRSA) becoming the predominant cause and representing a significant burden to the healthcare system. The last updated Infectious Diseases Society of America (IDSA) guidelines concerning MRSA infections and SSTIs management were published in 2011 and 2014, respectively. The UK updated guidelines for MRSA infection treatment were published in 2021. Older treatment options may be associated with toxicity and require frequent dosing. There is a paucity of recent reviews on the armamentarium of new agents for MRSA SSTIs treatment. Recent findingsSince 2005, several new antibiotics received a fast-track approval by the Food and Drug Administration (FDA) for SSTI treatment. These drugs include delafloxacin, omadacycline, tedizolid, ceftaroline, dalbavancin, oritavancin and telavancin. In this manuscript, we will review the data that led to these new drugs approval and discuss their advantages and disadvantages in MRSA SSTIs management. SummaryMRSA is a major cause of SSTIs. Several novel therapies covering MRSA were FDA-approved for SSTIs. However, the current IDSA guidelines for MRSA infection and SSTIs as well as the recently published UK guidelines on MRSA treatment only consider these drugs as alternative choices or do not mention them at all. Keywordsacute bacterial skin and skin structure infections, methicillin-resistant Staphylococcus aureus, skin and soft tissue infections admissions for SSTIs was increasing by 30% from 2000 to 2004, a more recent study showed a decrease of 15.8% in MRSA-related hospitalizations between 2010 and 2014 [7,8].Historically, community-acquired MRSA (CA-MRSA) was genetically different from hospitalacquired-MRSA (HA-MRSA) and could be clinically differentiated because it was essentially causing limited to uncomplicated SSTIs [9]. However, the

show abstract

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Cited by 17 publications

References 72 publications

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection

New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections

Contact Info

Product

Resources

About